
The FDA has approved three HIV products since June 2025, and the late-stage pipeline is testing how far apart doses can be spaced. Here are the milestones payers and health systems should track through 2027.
Approvable designations
Approvable designations
Fast-track designations
Priority review
Non-approvable designations






